Open Access by Heather E Eaton et al.
RESEARCH Open Access
Antibody dependent enhancement of frog virus 3
infection
Heather E Eaton, Emily Penny, Craig R Brunetti
*
Abstract
Background: Viruses included in the family Iridoviridae are large, icosahedral, dsDNA viruses that are subdivided
into 5 genera. Frog virus 3 (FV3) is the type species of the genus Ranavirus and the best studied iridovirus at the
molecular level. Typically, antibodies directed against a virus act to neutralize the virus and limit infection. Antibody
dependent enhancement occurs when viral antibodies enhance infectivity of the virus rather than neutralize it.
Results: Here we show that anti-FV3 serum present at the time of FV3 infection enhances infectivity of the virus in
two non-immune teleost cell lines. We found that antibody dependent enhancement of FV3 was dependent on
the Fc portion of anti-FV3 antibodies but not related to complement. Furthermore, the presence of anti-FV3 serum
during an FV3 infection in a non-immune mammalian cell line resulted in neutralization of the virus. Our results
suggest that a cell surface receptor specific to teleost cell lines is responsible for the enhancement.
Conclusions: This report represents the first evidence of antibody dependent enhancement in iridoviruses. The
data suggests that anti-FV3 serum can either neutralize or enhance viral infection and that enhancement is related
to a novel antibody dependent enhancement pathway found in teleosts that is Fc dependent.
Background
Following a viral infection an immune response is eli-
cited by the host, which includes both an innate and
adaptive response. During the adaptive immune
response, antibodies are produced that are designed to
recognize and neutralize a pathogen. Typically, viral
antibodies neutralize a virus by preventing the attach-
ment of specific cell surface receptors with viral glyco-
proteins, while also activating the complement system.
However, not all antibodies serve to reduce infectivity.
Antibody dependent enhancement (ADE) occurs when
viral antibodies enhance infectivity of a virus by promot-
ing the attachment of viral particles to cells. Virus speci-
fic antibodies bind to viral particles to form complexes
that can bypass normal routes of viral attachment and
entry. The virus+antibody complex allows for increased
viral entry or infection of cells that would not normally
become infected. Virus+antibody complexes therefore
result in a more efficient infection than with virus alone.
There are several mechanisms of how ADE can occur.
The most common mechanism of ADE is Fc receptor
(FcR)-dependent [1]. In FcR-dependent ADE the virus
+antibody complex binds to cells containing FcRs on
their surface. The interaction is mediated between the
exposed Fc region of the antibody (from the virus+anti-
body complex) and the FcR on the cell surface. FcRs are
found on a wide variety of cells of the immune system,
including macrophages, B cells, neutrophils, monocytes,
and granulocytes [2,3]. However, since not all cells that
exhibit ADE are immune cells, another mechanism
must be responsible for ADE in non-FcR bearing cells.
Complement-mediated ADE is not exclusive to FcR
bearing cells because complement receptors are found
on a large variety of cell types [4]. Complement-
mediated ADE occurs via binding between the Fc region
of antibodies and C1q [1]. This can result in a variety of
outcomes including the activation of complement,
which causes complement C3 fragment and viral surface
proteins to bind and promote viral attachment. C1q can
also enhance virus attachment by binding to C1qR on
the cell surface, which brings the virus into close proxi-
mity to cells.
ADE can result in increased viral pathogenesis because
it enhances a virus’s ability to bind to cells. It therefore
can result in increased severity of disease. This was first
shown with dengue virus where a second infection * Correspondence: craigbrunetti@trentu.ca
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higher levels of virus production [5,6]. An in vitro study
suggested that the mechanism behind ADE in dengue
virus was FcR-dependent [7-9]. Dengue virus titer was
enhanced dramatically through the binding of the virus
+antibody complex to FcRs found on cells of the
immune system [7-9].
While ADE has been demonstrated for many RNA
viruses, only a few DNA virus families, including pox-
viruses [10] and herpesviruses [11-13] have been shown
to use ADE as a mechanism of infection. While it is
suggested that they most likely use FcR-dependent ADE
[1], little is actually known about the mechanism of
ADE in the large DNA viruses. We decided to deter-
mine if viruses from the family Iridoviridae use ADE as
a mechanism of infection. Viruses in the family Iridoviri-
dae are large (~120-200 nm), icosahedral viruses that
contain a linear, double-stranded DNA genome. Irido-
virus infections appear to be restricted to invertebrates
(Iridovirus, Chloriridovirus) and poikilothermic verte-
brates (Lymphocystivirus, Ranavirus, Megalocytivirus)
[14]. Although iridoviruses are large DNA viruses, very
little is known about their biology. Using frog virus 3
(FV3; Ranavirus) as a model virus, we propose to inves-
tigate whether ADE occurs in viruses of the family Irido-
viridae, specifically in the Ranavirus genus.
Results
ADE increases FV3 infection in teleost cells
In order to investigate whether ADE occurs during an
FV3 infection, FV3 was pre-incubated with either rabbit
anti-FV3 serum (FV3+anti-FV3 serum) or rabbit pre-
immune serum (FV3+pre-immune serum). The FV3
+anti-FV3 serum and FV3+pre-immune serum com-
plexes were added to BF-2 (teleost fibroblast) or FHM
(teleost epithelial) cells. Two hours post-infection, BF-2
and FHM cells were overlaid with agarose and 48 hours
later the number of plaques produced by the virus were
counted and compared to the number of plaques from
an FV3 only control infection. All experiments were
repeated in at least 3 independent trials and mean
results are shown (Figure 1A, Additional file 1A). The
addition of 100 ng of anti-FV3 serum to the virus in
BF-2 cells resulted in an ~300% increase in the number
of plaques compared to pre-immune serum (Figure 1A).
Following the addition of the highest concentration of
anti-FV3 serum (300 ng), we found that the plaque
number was reduced as compared to an FV3 control
indicating that at high concentrations, anti-FV3 serum
can neutralize the infection (Figure 1A). Infection of
cells by FV3+anti-FV3 serum complexes also increased
the number of plaques in BF-2 cells compared to an
infection with FV3+pre-immune serum complexes as
seen by immunofluorescence (Figure 1B). Anti-FV3
serum staining revealed small plaques in cells infected
with FV3+ pre-immune serum complexes while cells
infected with FV3+anti-FV3 serum complexes showed
more frequent and larger sized plaques (Figure 1B). A
control experiment in which pre-immune serum or
anti-FV3 serum were added to cells without FV3
resulted in an absence of plaques. In another teleost cell
line (FHM), we observed a greater than 200% increase
in the number of plaques in the presence of 100 ng of
anti-FV3 serum (Figure 1C, Additional file 1B). This
data suggests that ADE occurs during an FV3 infection
in teleost cells.
Anti-FV3 serum neutralizes infection in BGMK cells
FV3 replicates in a variety of cell types including cells of
mammalian origin [15]. In order to determine whether
the ADE phenomenon occurs in mammalian cells along
with teleost cells, we pre-incubated FV3 with anti-FV3
serum or pre-immune serum and FV3+anti-FV3 serum
or FV3+pre-immune serum complexes were added to
BGMK (mammalian fibroblast) and BF-2 (teleost fibro-
blast) cells and the cells were overlaid with agarose.
Forty-eight hours later, the overlay was removed and
indirect immunofluorescence was used to visualize pla-
ques. In contrast to teleost cells (Fig 1A), the addition
of 100 ng of anti-FV3 serum to mammalian cells
resulted in an ~90% reduction in the number of plaques
compared to the pre-immune serum control (Figure 2A,
Additional file 2). Furthermore, the plaques produced by
an FV3 infection in BGMK cells were considerably smal-
ler than those seen in BF-2 cells (Figure 2B). These
results suggest that in mammalian cells anti-FV3 serum
does not enhance an FV3 infection but instead neutra-
lizes it. Thus, ADE does not occur in an FV3 infection
in mammalian fibroblast cells but does occur in teleost
fibroblast cells.
Addition of pre-immune serum to BF-2 cells inhibits ADE
of FV3 infectivity
In order to determine if the ADE was specific to anti-FV3
serum, we challenged cells with non-specific rabbit
serum to act as a competitive inhibitor of anti-FV3
serum. FV3+anti-FV3 serum (50 ng) or FV3+pre-
immune serum (50 ng) complexes were allowed to form
and were then added to cells along with increasing
amounts (0-1000 ng total serum) of non-specific rabbit
serum. Infected cells were incubated for 2 hours and
overlaid with agarose. Forty-eight hours later the plaques
were counted. The addition of increasing amounts of
non-specific competitive serum resulted in a reduction in
ADE (Figure 3, Additional file 3). At the highest concen-
tration of competitor, 1000 ng (20-fold excess), there was
an almost 300% reduction of FV3 ADE (Figure 3) as
compared to cells where pre-immune serum was not
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Page 2 of 11Figure 1 ADE occurs during an FV3 infection in teleost cells. FV3 (~50 PFU) was incubated alone, with rabbit anti-FV3 serum, or rabbit pre-
immune serum for 1 hour at 4°C and was then added to BF-2 or FHM cells. (A) Two hours post-infection, BF-2 cells were overlaid and 48 hours
later the plaques were stained with crystal violet and were counted. Plaque numbers are shown as a relative percentage of a control FV3
infection in the absence of serum. (B) Forty-eight hours post-overlay BF-2 cells were stained by indirect immunofluorescence using anti-FV3
serum (green) and DAPI (nuclei - blue). (C) FV3+anti-FV3 serum or FV3+rabbit pre-immune serum complexes were added to FHM cells and 24
hours later plaques were visualized by indirect immunofluorescence and counted. Plaque numbers were expressed as a relative percentage
compared to FHM cells infected with FV3 only. All experiments were completed in 3 independent trials and mean plaque numbers are shown.
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non-specific serum acts as a competitive inhibitor pre-
sumably binding to cell surface components that mediate
ADE.
Protein A eliminates ADE of FV3 infectivity
Since ADE occurs in an FV3 infection in teleost cells,
we next wanted to determine if the Fc portion of anti-
FV3 antibodies mediates ADE. Protein A binds to the
Fc region of an antibody, thereby blocking binding
between the Fc region of the antibody and FcRs and
complement proteins on the cell surface. Protein A (300
μg/mL) was pre-incubated with rabbit anti-FV3 serum
or rabbit pre-immune serum followed by the addition of
FV3. FV3+anti-FV3 serum/(+/-)protein A or FV3+pre-
immune serum/(+/-)protein A complexes were added to
cells and plaques were counted 48 hours later. The addi-
tion of protein A to anti-FV3 serum completely
Figure 2 Rabbit anti-FV3 serum neutralizes an FV3 infection in a mammalian cell line. Rabbit anti-FV3 serum (0-100 ng) or rabbit pre-
immune serum (0-100 ng) was incubated with FV3 (~50 PFU) before being added to BGMK or BF-2 cells for 2 hours. Once infected, BGMK cells
were incubated at 28°C with 5% CO2. The cells were subsequently overlaid with agarose. (A) Forty-eight hours post-overlay BGMK cells
underwent indirect immunofluorescence and plaques were counted. Plaque numbers from 3 independent trials were counted and mean plaque
values were compared to BGMK cells infected with FV3 only and values are shown as a relative percentage. (B) Forty-eight hours post-overlay,
BGMK and BF-2 cells were processed for indirect immunofluorescence using rabbit anti-FV3 serum (green) and DAPI (nuclei - blue).
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file 4A). Note that the abolishment in infectivity by pro-
tein A is so complete that the virus samples incubated
with protein A are indistinguishable from the pre-
immune control (Figure 4A). These results suggest that
the Fc portion of anti-FV3 antibodies is responsible for
mediating ADE. However, the addition of protein A to
serum can sometimes result in aggregation of the anti-
bodies, thereby reducing the amount of available anti-
body. In order to avoid this issue we incubated 300 μg/
mL of protein A on BF-2 cells for 30 minutes prior to
the addition of FV3+anti-FV3 serum or FV3+pre-
immune serum complexes. Forty-eight hours post-infec-
tion plaques were counted. The addition of protein A to
BF-2 cells prior to addition of anti-FV3 serum allowed
FV3+anti-FV3 serum complexes to form. However, we
obtained a complete abolishment of enhancement simi-
lar to that seen when protein A was pre-incubated with
FV3+anti-FV3 serum (Figure 4A, Additional file 4B).
These results suggest that ADE of FV3 infectivity can be
inhibited by protein A and is likely Fc-dependent.
ADE of FV3 infectivity is complement-independent
To determine whether FV3 ADE was complement-
dependent, anti-FV3 serum and pre-immune serum
were heat-inactivated to inactivate complement, or incu-
bated with either EGTA or zymosan A. EGTA is a che-
lator that inhibits the classical complement pathway,
while zymosan A disrupts the alternative complement
pathway. Treated anti-FV3 serum or pre-immune serum
was incubated with FV3 before addition to BF-2 cells.
Forty-eight hours post-overlay plaques were counted.
Infection by the FV3+anti-FV3 serum complexes treated
with heat-inactivation, EGTA, or zymosan A did not
reduce the ADE of FV3 infectivity as compared to the
untreated FV3+anti-FV3 serum control (Figure 4B,
Additional file 5A, 5B, 5C). Regardless of whether high
or low levels of complement activity were present at the
time of infection, enhancement was not affected by
complement inhibitors suggesting that inactivation of
complement does not disrupt ADE of FV3 infectivity.
Fc binding proteins on teleost cells
The ability of anti-FV3 serum to neutralize an infection
in BGMK cells (mammalian fibroblast) and enhance
infection in BF-2 and FHM cells (teleost fibroblast and
epithelial respectively) suggests that teleost cells may
contain an Fc-binding component absent from BGMK
cells. Since the pre-immune control serum was able to
act as a competitive inhibitor (Figure 3), it suggests that
there must be a specific component on teleost cells that
the serum is binding to. A western blot containing
BGMK, BF-2, and FHM cellular extracts was probed
with rabbit pre-immune serum to determine if the
serum bound to any cellular proteins. While rabbit
serum was unable to bind to any proteins in BGMK
Figure 3 Addition of rabbit pre-immune serum to BF-2 cells inhibits ADE. FV3 (~50 PFU) was incubated with either 50 ng of rabbit anti-
FV3 serum or 50 ng rabbit pre-immune serum. FV3+anti-FV3 serum or FV3+pre-immune serum complexes were added to BF-2 cells along with
varying amounts of pre-immune serum (0-1000 ng). Cells were overlaid and plaques were visualized with crystal violet. Mean plaques values
from 3 independent trials were obtained and mean values were expressed as a relative percentage to BF-2 cells infected with FV3 in the
absence of anti-FV3 serum or pre-immune serum.
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95 kDa were detected in BF-2 and FHM cells probed
with rabbit pre-immune serum (Figure 5A). No bands
were detected either on a control blot where the pri-
mary rabbit serum was omitted (Figure 5C) or on a
membrane where pre-immune serum was pre-incubated
with protein A (Figure 5B), which binds to the Fc por-
tion of the antibody. These data suggest that the Fc por-
tion of the antibody bound to the 38 kDa and 95 kDa
proteins and that the variable region of the antibody
does not mediate this interaction. The experiment was
repeated several times using an unrelated rabbit serum
and results consistent with Figure 5 were obtained (data
not shown). This data suggests that an Fc binding com-
ponent specific to fibroblast and epithelial teleost cells
may play a role in ADE of an FV3 infection.
Discussion
While ADE has been previously reported for some large
DNA viruses, including herpesviruses [11-13] and pox-
viruses [10], no studies to date have demonstrated ADE
as a mechanism to enhance infections in iridoviruses.
This paper provides the first evidence of ADE in irido-
viruses, specifically in the Ranavirus genus.
Figure 4 ADE in FV3 is Fc-dependent and independent of complement. (A) Protein A (300 μg/mL) was either incubated with BF-2 cells or
anti-FV3 serum and pre-immune serum for 30 minutes at room temperature. FV3 (~50 PFU) was incubated with anti-FV3 serum or pre-immune
serum and was then added to BF-2 cells (+/- protein A) and were overlaid 2 hours later. FV3 (~50 PFU) was incubated with anti-FV3 serum or
pre-immune serum (+/- protein A) and then was added to BF-2 cells and were overlaid 2 hours later. Forty-eight hours post-overlay plaques
were counted and expressed as a relative percentage of a control FV3 infection. (B) Rabbit anti-FV3 serum or rabbit pre-immune serum were
heat-inactivated or incubated with zymosan A or EGTA for one hour before the addition of FV3 (~50 PFU). FV3+anti-FV3 serum or FV3+pre-
immune serum complexes were added to BF-2 cells, which were subsequently overlaid. Forty-eight hours post-overlay, plaques were counted
and were compared as a relative percentage to BF-2 cells infected with FV3 in the absence of serum. Experiments were completed in at least 3
independent trials with mean plaque values shown.
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to either neutralize or enhance an FV3 infection
depending on the cell line. Although the infection was
less efficient in mammalian cells, FV3 exhibited the abil-
ity to enter the cell and spread as was revealed by the
presence of numerous plaques post-infection. The addi-
t i o no fa n t i - F V 3s e r u mt oa nF V 3i n f e c t i o ni nB G M K
cells dramatically reduced plaque number and size
demonstrating the ability of the anti-FV3 serum to neu-
tralize the infection in a mammalian cell line. However,
the opposite effect was seen in teleost (BF-2 and FHM)
cell lines. ADE often occurs with neutralizing antibodies
at sub-neutralizing concentrations and differences in the
interaction between virus and antibody can lead to
either neutralization or enhancement of a viral infection
[16]. Furthermore, enhancement of an infection is parti-
cularly sensitive to this interaction and can also involve
the target cell. Our data suggests that the anti-FV3
serum used in this study possess both neutralizing and
enhancing activity, depending on various factors includ-
ing the cell type and the concentration of antibody.
Ranaviruses, including FV3, have been isolated from a
variety of species including fish and amphibians. While
FV3 has never been isolated from fish in vivo, other clo-
sely related (over 98% sequence identity of the major
capsid protein [17]) ranaviruses, including epizootic hae-
matopoietic necrosis virus (EHNV) and Bohle virus
(BIV) infect fish and infection can result in high levels
of morbidity and mortality [18-20]. FV3 shows high
levels of infectivity in fish cell lines in vitro [21-23];
therefore two fish cells lines (BF-2 and FHM) were used
during this study. While there are many differences
from mammalian immune systems, the immune systems
of fish and amphibians are fundamentally similar to
mammals with both innate immunity and adaptive
immune functions [24,25]. However, immunoglobins of
lower vertebrates are currently poorly understood as
compared to those of mammals. Fish were the first
group to have demonstrated antibody activity and have
one predominant Ig isotype, an IgM-like tetrameric
molecule [26]. Amphibians have several isotypes includ-
ing IgY, which is the predominant isotype in amphibians
and is considered the functional equivalent to mamma-
lian IgG [27-29]. However, the adaptive immune system
of mammals is fundamentally similar to that of lower
vertebrates and is characterized by T cell receptors, Ig,
and the major histocompatibility complex (MHC).
Lower vertebrates also rely heavily on non-specific
defense systems for pathogen defense and therefore the
innate immune system of lower vertebrates, including
complement, is diverse and similar to that of higher ver-
tebrates. We therefore suspect that the mechanisms
behind ADE in fish and amphibians will be similar to
that of mammals. While we feel the mechanisms behind
ADE to be similar between fish, amphibians, and mam-
mals, there are some inherent differences between the
immune systems of each species. It will be important to
confirm these experiments in the future using sera from
either immunized frogs or fish.
Common mechanisms behind ADE can be dependent
on either complement or FcRs. Our results suggest that
complement pathways (classical or alternative) do not
play a role in the enhancement of FV3 infection by anti-
FV3 serum. However, protein A eliminated any
enhancement of the anti-FV3 serum suggesting the
mechanism behind FV3 ADE to be FcR-dependent.
Figure 5 Rabbit serum binds to two proteins (38 kDa and 95 kDa) on teleost cells. BGMK, BF-2, and FHM cells were harvested and run on
a 10% SDS acrylamide gel. Proteins were transferred from the gel to a PVDF membrane. The membrane was probed with (A) rabbit pre-
immune serum, (B) rabbit pre-immune serum pre-incubated with protein A, or (C) no primary serum was added. Proteins were then visualized
using peroxidase conjugated goat anti-rabbit IgG and chemiluminescence.
Eaton et al. Virology Journal 2010, 7:41
http://www.virologyj.com/content/7/1/41
Page 7 of 11Many virus families, including other DNA viruses,
enhance viral infection through the binding of the Fc
region of anti-viral antibodies to FcR on the surface of
cells of the immune system [30-37]. However, this result
is intriguing because both cell lines that exhibited ADE
(BF-2 and FHM) in this study are non-immune (fibro-
blast and epithelial, respectively) cell lines that should
lack FcR on the cell surface [2,3,9]. While recent
research suggests that teleosts and amphibians possess
both FcR homologs and novel immune-type receptors
(NITRs) [38-42], little is known about their tissue distri-
bution and role in innate immunity. FcRs in humans are
a variety of sizes that can range from 40 kDa to over 70
kDa [43-46], while one previously identified FcR in fish
was predicted to be ~33 kDa in size [40]. We identified
two proteins (38 kDa and 95 kDa) in teleost cells (but
not in a mammalian cell line) that bound to the Fc
region of rabbit antibodies. The molecular weight of
these proteins does not rule out the possibility that they
may function as novel FcRs in teleosts. While we do not
specifically know what the anti-FV3 serum is binding to
mediate ADE, the results suggest that proteins specific
to teleost cells bind to the Fc region of antibodies
potentially mediating ADE.
Iridovirus infections of increased pathogenicity have
been recently observed in several wild and cultivated
fish and amphibian species [17,47,48]. Specifically, rana-
virus infections pose a potential threat to amphibians
and have been implicated in the widespread decline of
worldwide amphibian populations [48,49]. There have
recently been increasing reports of ranavirus infections,
with both the severity of infections and the number of
species infected increasing [17,50-55]. While evidence
suggests that an iridovirus infection mounts a strong
immune response [56,57], this does not eliminate the
possibility that viral infection can be enhanced under
certain circumstances. Although humoral immunity is
required for protection against viruses, antibodies at
sub-neutralizing concentrations may enhance, rather
than protect against infection [16]. It is also possible
that the virus utilizes ADE as a method for more effi-
cient entry. Regardless of whether a strong immune
response is mounted, ADE may promote increased entry
or entry into cells not usually infected. In particular,
ADE in immunocompromised individuals may allow for
increased infection. Furthermore, the link between ADE
in vitro and in vivo currently remains elusive. For
instance, ADE of dengue viruses has been well docu-
mented and extensively characterized in vitro,b u tin
vivo studies remain unclear and controversial [58-60]. It
will be important for future experiments to confirm
these in vitro studies using live fish and frogs. Ranavirus
infections are spreading rapidly worldwide, however, the
reasons behind this rapid spread are currently unknown
and are most likely complex. While FV3 ADE has yet to
be demonstrated in vivo, a strong second infection of
FV3 may explain the increased severity and prevalence
of ranavirus infections. Therefore, ADE may represent a
potential hypothesis for the recent emergence and
increased severity of ranavirus infections.
Conclusions
This study demonstrates for the first time that FV3, an
iridovirus, utilizes ADE to increase infection in vitro.
The anti-FV3 serum used in this study both enhanced
and neutralized a viral infection depending on cell type
and concentration. The mechanism behind enhance-
ment was found to be independent of complement but
dependent upon the Fc region of anti-FV3 antibodies.
The addition of protein A to either anti-FV3 serum or
teleost cells completely abolished ADE. This result was
surprisingly because two non-immune cell lines most
likely lacking FcR were used during this experiment.
Our results suggests that the Fc region of anti-FV3 anti-
bodies may promote viral entry through novel Fc bind-
ing activity on teleost cells.
Methods
Cell lines and virus
Bluegill fry (BF-2) cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and
w e r eg r o w na t2 8 ° Ci n5 %C O 2 in Eagle’s Minimal
Essential medium with Earle’s balanced salts (EMEM;
HyClone, Ottawa, ON) and 2 mM L-glutamine supple-
mented with 10% fetal bovine serum (FBS), 1.0 mM
sodium pyruvate, 0.1 mM nonessential amino acids, and
antibiotics (100 U/mL penicillin and 100 g/mL strepto-
mycin). Baby green monkey kidney (BGMK) cells were
obtained from ATCC and were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM; HyClone) sup-
plemented with 7% FBS, 2 mM L-glutamine, penicillin
(100 U/mL), and streptomycin (100 g/mL) at 37°C with
5% CO2. We have previously characterized an FV3
infection in BGMK cells [61]. Fathead minnow (FHM)
cells were also obtained from ATCC and were main-
tained at 30°C in minimum essential medium with
Hanks’ salts (MEM; Invitrogen, Burlington, ON) supple-
mented with 10% FBS, penicillin (100 U/mL), and strep-
tomycin (100 g/mL). FV3 was obtained from ATCC and
rabbit anti-FV3 serum and rabbit pre-immune serum
were kindly provided by V.G. Chinchar (University of
Mississippi Medical Center, Jackson, MS). Once BGMK
cells were infected with FV3 they were incubated at 28°
C with 5% CO2.
ADE plaque assay
FV3 (~50 PFU) was mixed with either rabbit anti-FV3
serum or control rabbit pre-immune serum (0 ng, 10
Eaton et al. Virology Journal 2010, 7:41
http://www.virologyj.com/content/7/1/41
Page 8 of 11ng, 50 ng, 100 ng, 200 ng, and 300 ng total serum pro-
tein) for a final volume of 100 μL in media and was
incubated for 1 hour at 4°C. The FV3+anti-FV3 serum
or FV3+pre-serum complexes were then added to BF-2,
FHM, or BGMK cells grown to 90% confluence in 6-
well plates. BF-2 and BGMK cells were overlaid with 2%
agarose 2 hours post-infection. Forty-eight hours post-
overlay cells were either stained with crystal violet
(0.05%) or underwent indirect immunofluorescence and
plaques were counted. FHM cells were incubated for 24
hours and indirect immunofluorescence was carried out
and plaques were counted.
Pre-immune serum challenge
Rabbit anti-FV3 serum (50 ng total serum protein) or
rabbit pre-immune serum (50 ng total serum protein)
were mixed with FV3 (~50 PFU) in a final volume of
100 μL in EMEM and were incubated for 1 hour at 4°C.
Pre-immune serum was added to BF-2 cells grown to
90% confluence in 6-well dishes for final concentrations
of 0 ng/μL, 0.1 ng/μL, 0.5 ng/μL, and 1 ng/μL. FV3
+anti-FV3 serum or FV3+pre-immune serum complexes
were added to BF-2 cells containing pre-immune serum
and were incubated for 2 hours. Cells were overlaid
with 2% agarose and 48 hours post-overlay crystal violet
(0.05%) was added to cells and plaques were counted.
Inhibition of Fc and complement
Rabbit anti-FV3 serum (0-150 ng total serum protein) or
rabbit pre-immune serum (0-150 ng total serum pro-
tein) were incubated with protein A (300 μg/mL; Sigma,
Oakville, ON) or EGTA (0.05 M) for 30 minutes at
room temperature, zymosan A (20 mg/mL; Sigma) for 1
hour at 37°C, or were heat-inactivated at 56°C for 30
minutes. Approximately 50 PFU of FV3 was added and
the FV3+anti-FV3 serum or FV3+pre-immune serum
complexes were brought up to a final volume of 100 μL
with serum-free EMEM. An ADE plaque assay in BF-2
cells was then performed. Protein A (300 μg/mL) was
incubated with BF-2 cells for 30 minutes at room tem-
perature. Cells were washed several times with PBS and
50 PFU of FV3 previously incubated with 0-150 ng anti-
FV3 serum or pre-immune serum for one hour at 4°C
were added to the cells. An ADE plaque assay using 0
ng, 10 ng, 50 ng, 100 ng, and 150 ng of rabbit anti-FV3
serum or control rabbit pre-immune serum was then
performed.
Indirect immunofluorescence
Cells were fixed for 10 minutes in 3.7% paraformalde-
hyde in phosphate buffer saline (PBS). Following several
washes, cells were incubated in block buffer (5% bovine
serum albumin (BSA) (w/v), 50 mM Tris HCl (pH 7.4),
150 mM NaCl, 0.5% NP-40 (v/v)) overnight at 4°C. Cells
were incubated with rabbit anti-FV3 serum (dilution: 1/
1000) for one hour at room temperature. Cells were
then incubated in FITC-conjugated goat anti-rabbit
immunoglobulin G (IgG) (dilution: 1/100) (Jackson
ImmunoResearch Inc., West Grove, PA) and Texas
Red®-X Phalloidin (dilution 1/40) (Invitrogen) for one
hour at room temperature. Finally, cells were incubated
for 2 minutes in the nucleic acid stain DAPI (Invitro-
gen) diluted to 300 nM in PBS. Immunofluorescence
was detected using a Leica DM6000 B fluorescent
microscope (Leica, Wetzlar, Germany). Images were
assembled using Adobe Photoshop CS4 (Adobe, San
Jose, CA).
Western Blotting
BGMK, BF-2, and FHM cells grown to 100% confluence
in a 6-well dish were scraped into the media and centri-
fuged at 10,000 × g for 5 minutes. The supernatant was
removed and the cells were re-suspended in Laemmli
reducing buffer [62]. Cell lysates were boiled and pro-
teins were separated on a 10% polyacrylamide gel using
sodium dodecyl sulfate (SDS) running buffer (125 mM
Tris, 1.25 M glycine, 0.5% SDS). Following electrophor-
esis, the proteins were transferred from the gel to a
polyvinylidene difluoride (PVDF) membrane using a
semi-dry transfer apparatus (FisherBiotech, Pittsburgh,
PA). The membrane was blocked overnight at 4°C in
TBST buffer (140 mM NaCl, 24 mM Tris (pH 7.4), 0.2%
Tween® 20, 3 mM KCl) containing 5% non-fat milk
powder. The membrane was incubated without primary
serum, rabbit pre-immune serum (dilution 1:1000), rab-
bit pre-immune serum pre-incubated with 300 μg/mL
protein A for 30 minutes at room temperature (dilution
1:1000), or a second unrelated rabbit pre-immune
serum (dilution 1:1000) for 1 hour shaking at room tem-
perature. The membrane was washed several times then
incubated for 1 hour shaking at room temperature in
peroxidase-conjugated AffiniPure F(ab’)2 fragment goat
anti-rabbit IgG (Jackson ImmunoResearchInc.) diluted
1/10,000. The membrane was washed several times and
proteins were detected by applying Chemiluminescence
Reagent Plus (Perkin-Elmer, Boston, MA) to the mem-
brane as per the manufacture’sp r o t o c o l .T h ei m a g e s
were then viewed using a Genius
2 Bio Imaging System
(Syngene, Frederick, MD).
Additional file 1: ADE occurs during an FV3 infection. ADE occurs
during an FV3 infection in (A) BF-2 and (B) FHM cells. Original plaque
numbers and standard error from three individual experiments are
shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-41-
S1.XLS]
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Page 9 of 11Additional file 2: Rabbit anti-FV3 serum neutralizes an FV3 infection
in BGMK cells. Original plaque numbers and standard error from three
individual experiments are shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-41-
S2.XLS]
Additional file 3: Addition of rabbit pre-immune serum to BF-2 cells
inhibits ADE. Original plaque numbers and standard error from three
individual experiments are shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-41-
S3.XLS]
Additional file 4: ADE in FV3 is Fc-dependent. Protein A incubated
with either (A) anti-FV3 serum or (B) BF-2 cells abolished ADE in BF-2
cells. Original plaque numbers and standard error from three individual
experiments are shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-41-
S4.XLS]
Additional file 5: ADE in FV3 is complement independent. Treatment
of anti-FV3 serum with (A) heat inactivation, (B) EGTA, and (C) zymosan A
did not affect ADE. Original plaque numbers and standard error from
three individual experiments are shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-41-
S5.XLS]
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